CN105120883B - 抗生素化合物的盐酸盐 - Google Patents

抗生素化合物的盐酸盐 Download PDF

Info

Publication number
CN105120883B
CN105120883B CN201480013969.0A CN201480013969A CN105120883B CN 105120883 B CN105120883 B CN 105120883B CN 201480013969 A CN201480013969 A CN 201480013969A CN 105120883 B CN105120883 B CN 105120883B
Authority
CN
China
Prior art keywords
amino
compound
pharmaceutical composition
compound according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480013969.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105120883A (zh
Inventor
张伟江
龙尼·张
迪米塔尔·菲利波夫
杰克·格林
李均宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma Antibiotics IP LLC
Original Assignee
Theravance Biopharma Antibiotics IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma Antibiotics IP LLC filed Critical Theravance Biopharma Antibiotics IP LLC
Publication of CN105120883A publication Critical patent/CN105120883A/zh
Application granted granted Critical
Publication of CN105120883B publication Critical patent/CN105120883B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201480013969.0A 2013-03-13 2014-03-06 抗生素化合物的盐酸盐 Active CN105120883B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779065P 2013-03-13 2013-03-13
US61/779,065 2013-03-13
PCT/US2014/021064 WO2014158952A1 (en) 2013-03-13 2014-03-06 Hydrochloride salts of an antibiotic compound

Publications (2)

Publication Number Publication Date
CN105120883A CN105120883A (zh) 2015-12-02
CN105120883B true CN105120883B (zh) 2017-11-17

Family

ID=50483481

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480013969.0A Active CN105120883B (zh) 2013-03-13 2014-03-06 抗生素化合物的盐酸盐

Country Status (32)

Country Link
US (1) US9161990B2 (enExample)
EP (1) EP2968446B1 (enExample)
JP (3) JP6482523B2 (enExample)
KR (1) KR20150126659A (enExample)
CN (1) CN105120883B (enExample)
AR (1) AR095044A1 (enExample)
AU (1) AU2014241481B9 (enExample)
BR (1) BR112015022716A2 (enExample)
CA (1) CA2902720A1 (enExample)
CY (1) CY1119316T1 (enExample)
DK (1) DK2968446T3 (enExample)
EA (1) EA027282B1 (enExample)
ES (1) ES2633964T3 (enExample)
GE (1) GEP20186874B (enExample)
HR (1) HRP20171188T1 (enExample)
HU (1) HUE033738T2 (enExample)
IL (1) IL240663A0 (enExample)
LT (1) LT2968446T (enExample)
MD (1) MD4599C1 (enExample)
ME (1) ME02854B (enExample)
MX (1) MX361984B (enExample)
PH (1) PH12015502060A1 (enExample)
PL (1) PL2968446T3 (enExample)
PT (1) PT2968446T (enExample)
RS (1) RS56141B1 (enExample)
SG (1) SG11201507235YA (enExample)
SI (1) SI2968446T1 (enExample)
SM (1) SMT201700369T1 (enExample)
TW (1) TWI608845B (enExample)
UA (1) UA115086C2 (enExample)
WO (1) WO2014158952A1 (enExample)
ZA (1) ZA201506748B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2980537A1 (en) * 2015-03-24 2016-09-29 Elevance Renewable Sciences, Inc. Polyol esters of metathesized fatty acids and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092183A2 (en) * 2003-04-16 2004-10-28 Sandoz Ag Processes for the preparations of cefepime
WO2005042568A2 (en) * 2003-10-22 2005-05-12 Theravance, Inc. Hydrochloride salts of a glycopeptide phosphonate derivative
US20080194464A1 (en) * 2001-10-12 2008-08-14 Fatheree Paul R Cross-linked glycopeptide-cephalosporin antibiotics

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434287A (en) * 1975-02-20 1984-02-28 Ciba-Geigy Corporation Cephalosporin derivatives
AR229883A1 (es) 1978-05-26 1983-12-30 Glaxo Group Ltd Procedimiento para la preparacion de antibiotico(6r,7r)-7-((z)-2-(2-aminotiazol-4-il)-2-(2-carboxiprop-2-oxiimino)-acetamido)-3-(1-piridinometil)-cef-3-em-4-carboxilato
US4626534A (en) 1984-07-23 1986-12-02 Eli Lilly And Company Pharmaceutical formulation
DE3801179A1 (de) 1988-01-18 1989-07-27 Hoechst Ag Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten
JPH0331449A (ja) 1989-06-27 1991-02-12 Yamaha Corp リードフレーム用Fe―Ni合金
DE69004921T2 (de) 1989-09-30 1994-05-05 Eisai Co Ltd Injizierbare Cephalosporinpräparate und ihre Anwendung.
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JP4142149B2 (ja) 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
ATE450540T1 (de) 2003-05-23 2009-12-15 Theravance Inc Quervernetzte glycopeptid-cephalosporin- antibiotika
US6878868B2 (en) 2003-06-24 2005-04-12 Mcmillan Stacy L. Portable high-hat device
US7067482B2 (en) 2003-07-11 2006-06-27 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
EP1656930A1 (en) 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
US20080103121A1 (en) 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
FR2932177B1 (fr) 2008-06-06 2012-11-30 Inst Francais Du Petrole Procede d'hydrogenation selective sur un catalyseur contenant de l'or.
JP2010105965A (ja) 2008-10-30 2010-05-13 Taiyo Yakuhin Kogyo Kk バンコマイシン製剤
US8431539B2 (en) 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
US20110124551A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194464A1 (en) * 2001-10-12 2008-08-14 Fatheree Paul R Cross-linked glycopeptide-cephalosporin antibiotics
WO2004092183A2 (en) * 2003-04-16 2004-10-28 Sandoz Ag Processes for the preparations of cefepime
WO2005042568A2 (en) * 2003-10-22 2005-05-12 Theravance, Inc. Hydrochloride salts of a glycopeptide phosphonate derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A Multivalent Approach to Drug Discovery for Novel Antibiotics;Daniel D. Long,;《The Journal of Antibiotics》;20081231;第61卷(第10期);595-602 *

Also Published As

Publication number Publication date
WO2014158952A1 (en) 2014-10-02
TWI608845B (zh) 2017-12-21
AU2014241481B2 (en) 2018-02-01
DK2968446T3 (en) 2017-08-28
GEP20186874B (en) 2018-06-25
EP2968446A1 (en) 2016-01-20
IL240663A0 (en) 2015-10-29
ZA201506748B (en) 2017-08-30
AR095044A1 (es) 2015-09-16
MD4599C1 (ro) 2019-06-30
CN105120883A (zh) 2015-12-02
ME02854B (me) 2018-04-20
CA2902720A1 (en) 2014-10-02
MD4599B1 (ro) 2018-11-30
AU2014241481A1 (en) 2015-10-01
MX2015012170A (es) 2015-11-30
MD20150101A2 (ro) 2016-02-29
EA027282B1 (ru) 2017-07-31
TW201444572A (zh) 2014-12-01
JP2018177817A (ja) 2018-11-15
JP6482523B2 (ja) 2019-03-13
AU2014241481B9 (en) 2018-02-15
MX361984B (es) 2018-12-19
LT2968446T (lt) 2017-07-25
UA115086C2 (uk) 2017-09-11
PT2968446T (pt) 2017-07-27
SMT201700369T1 (it) 2017-09-07
HK1214524A1 (en) 2016-07-29
HRP20171188T1 (hr) 2017-10-06
PH12015502060A1 (en) 2016-01-25
US9161990B2 (en) 2015-10-20
SG11201507235YA (en) 2015-10-29
SI2968446T1 (sl) 2017-08-31
JP2016513642A (ja) 2016-05-16
HUE033738T2 (hu) 2018-01-29
KR20150126659A (ko) 2015-11-12
CY1119316T1 (el) 2018-02-14
PL2968446T3 (pl) 2017-11-30
US20140274877A1 (en) 2014-09-18
JP2017082016A (ja) 2017-05-18
EA201591697A1 (ru) 2016-02-29
RS56141B1 (sr) 2017-10-31
EP2968446B1 (en) 2017-05-03
ES2633964T3 (es) 2017-09-26
BR112015022716A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
US7115564B2 (en) Stable pharmaceutical compositions of dalbavancin and methods of administration
JP2010254701A (ja) 架橋グリコペプチド−セファロスポリン抗生物質
JP2009256358A (ja) 架橋グリコペプチド−セファロスポリン抗生物質
AU772633B2 (en) Echinocandin/carbohydrate complexes
US20120184497A1 (en) Dalbavancin compositions for treatment of bacterial infections
US20170190744A1 (en) Dalbavancin compositions for treatment of bacterial
NO345529B1 (no) Dalbavancin-materialer for behandling av bakterielle infeksjoner
US6841661B2 (en) Glycopeptide antibacterial compounds, compositions containing same and methods of using same
CN105120883B (zh) 抗生素化合物的盐酸盐
HK1214524B (en) Hydrochloride salts of an antibiotic compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant